Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Poliomyelitis virus type 1 (live, attenuated) is a biologic vaccine containing a weakened form of the wild-type poliovirus serotype 1. It is administered orally and stimulates active immunity by inducing both humoral and mucosal immune responses against poliovirus. The live-attenuated strains used in this vaccine were originally developed by Albert Sabin. The primary indication is the prevention of poliomyelitis caused by infection with wild-type or circulating vaccine-derived polioviruses. This oral polio vaccine has played a central role in global polio eradication efforts due to its ability to induce strong intestinal immunity and interrupt person-to-person transmission.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on poliomyelitis virus type 1 (live, attenuated).